Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases
Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
- Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
- Calluna is developing novel therapies that harness the transformative potential of the body's immune system.
- As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases.
- The Company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.